Keros Therapeutics (KROS) Stock Forecast & Price Target

Compare

346 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KROS Analyst Ratings

Moderate Buy

6 Buy

6 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Keros

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KROS Stock 12 Month Forecast

Average Price Target

$22.00

▲(60.47% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $22.00 with a high forecast of $35.00 and a low forecast of $13.00. The average price target represents a 60.47% change from the last price of $13.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","21":"$21","34":"$34","47":"$47","60":"$60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,21,34,47,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,15.910769230769231,17.501538461538463,19.092307692307692,20.683076923076925,22.273846153846154,23.864615384615384,25.455384615384617,27.046153846153846,28.636923076923075,30.22769230769231,31.818461538461538,33.40923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,14.910769230769231,15.501538461538463,16.092307692307692,16.683076923076925,17.273846153846154,17.864615384615384,18.455384615384617,19.046153846153846,19.636923076923075,20.22769230769231,20.818461538461538,21.409230769230767,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,14.218461538461538,14.116923076923078,14.015384615384615,13.913846153846155,13.812307692307693,13.71076923076923,13.60923076923077,13.507692307692308,13.406153846153845,13.304615384615385,13.203076923076923,13.101538461538462,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.79,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$22.00

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andreas Argyrides

Oppenheimer

$23

Buy

67.76%

Upside

Reiterated

08/08/25

Oppenheimer Sticks to Their Buy Rating for Keros Therapeutics (KROS)We reiterate our Outperform rating following the 2Q25 update.

Andres Y. Maldonado

H.C. Wainwright

$25→$20

Buy

45.88%

Upside

Reiterated

08/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (NYSE: AMN), Keros Therapeutics (NASDAQ: KROS) and Evolent Health (NYSE: EVH)

Dex Genotek

TR | OpenAI - 4o

$14→$13

Hold

-5.18%

Downside

Reiterated

08/08/25

AI Generated ArticleAI Generated Article

Thomas Smith

Leerink Partners

$35

Buy

155.29%

Upside

Reiterated

08/07/25

Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics

Yun Zhong

Wedbush

$15

Hold

9.41%

Upside

Reiterated

08/07/25

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

08/06/25

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/06/25

Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating

Jason Zemansky

Bank of America Securities

$18

Hold

31.29%

Upside

Downgraded

06/10/25

Keros Therapeutics downgraded to Neutral from Buy at BofAKeros Therapeutics downgraded to Neutral from Buy at BofA

Greg Harrison

Scotiabank

$26

Buy

89.64%

Upside

Reiterated

06/10/25

Keros Therapeutics (KROS) Receives a Buy from Scotiabank

Tiago Fauth

Wells Fargo

$28→$26

Buy

89.64%

Upside

Reiterated

06/09/25

Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

05/30/25

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

Vamil Divan

Guggenheim

―

Hold

―

Reiterated

05/29/25

Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Prakhar Agrawal

Cantor Fitzgerald

―

Hold

―

Downgraded

01/21/25

Keros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldKeros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Joseph Catanzaro

Piper Sandler

$40→$15

Buy

9.41%

Upside

Reiterated

01/17/25

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

Kelly Shi

Jefferies

$113→$23

Buy

67.76%

Upside

Reiterated

12/13/24

Keros Therapeutics (KROS) PT Lowered to $23 at JefferiesJefferies analyst Kelly Shi lowered the price target on Keros Therapeutics (NASDAQ: KROS) to $23.00 (from $113.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andreas Argyrides

Oppenheimer

$23

Buy

67.76%

Upside

Reiterated

08/08/25

Oppenheimer Sticks to Their Buy Rating for Keros Therapeutics (KROS)We reiterate our Outperform rating following the 2Q25 update.

Andres Y. Maldonado

H.C. Wainwright

$25→$20

Buy

45.88%

Upside

Reiterated

08/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (NYSE: AMN), Keros Therapeutics (NASDAQ: KROS) and Evolent Health (NYSE: EVH)

Dex Genotek

TR | OpenAI - 4o

$14→$13

Hold

-5.18%

Downside

Reiterated

08/08/25

AI Generated ArticleAI Generated Article

Thomas Smith

Leerink Partners

$35

Buy

155.29%

Upside

Reiterated

08/07/25

Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics

Yun Zhong

Wedbush

$15

Hold

9.41%

Upside

Reiterated

08/07/25

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

08/06/25

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/06/25

Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating

Jason Zemansky

Bank of America Securities

$18

Hold

31.29%

Upside

Downgraded

06/10/25

Keros Therapeutics downgraded to Neutral from Buy at BofAKeros Therapeutics downgraded to Neutral from Buy at BofA

Greg Harrison

Scotiabank

$26

Buy

89.64%

Upside

Reiterated

06/10/25

Keros Therapeutics (KROS) Receives a Buy from Scotiabank

Tiago Fauth

Wells Fargo

$28→$26

Buy

89.64%

Upside

Reiterated

06/09/25

Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

05/30/25

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

Vamil Divan

Guggenheim

―

Hold

―

Reiterated

05/29/25

Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Prakhar Agrawal

Cantor Fitzgerald

―

Hold

―

Downgraded

01/21/25

Keros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldKeros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Joseph Catanzaro

Piper Sandler

$40→$15

Buy

9.41%

Upside

Reiterated

01/17/25

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

Kelly Shi

Jefferies

$113→$23

Buy

67.76%

Upside

Reiterated

12/13/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Keros Therapeutics

1 Month

xxx

Success Rate

13/22 ratings generated profit

Average Return

+3.95%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +3.95% per trade.

3 Months

xxx

Success Rate

12/22 ratings generated profit

Average Return

+21.45%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +21.45% per trade.

1 Year

Joseph CatanzaroPiper Sandler

Success Rate

11/22 ratings generated profit

Average Return

+4.51%

reiterated a buy rating 7 months ago

Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.51% per trade.

2 Years

xxx

Success Rate

8/28 ratings generated profit

Average Return

-34.07%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -34.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KROS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KROS has received 5 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. KROS average Analyst price target in the past 3 months is 22.00.

Each month's total comprises the sum of three months' worth of ratings.

KROS Financial Forecast

KROS Earnings Forecast

Next quarter’s earnings estimate for KROS is -$1.00 with a range of -$1.47 to -$0.26. The previous quarter’s EPS was -$0.76. KROS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.35% of the time in the same period. In the last calendar year KROS has Outperformed its overall industry.

KROS Sales Forecast

Next quarter’s sales forecast for KROS is $7.13M with a range of $0.00 to $19.01M. The previous quarter’s sales results were $18.17M. KROS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.82% of the time in the same period. In the last calendar year KROS has Outperformed its overall industry.

KROS Stock Forecast FAQ

What is KROS’s average 12-month price target, according to analysts?

Based on analyst ratings, Keros Therapeutics, Inc.’s 12-month average price target is 22.00.

What is KROS’s upside potential, based on the analysts’ average price target?

Keros Therapeutics, Inc. has 60.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KROS a Buy, Sell or Hold?

Keros Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 6 hold ratings and 0 sell ratings.

What is Keros Therapeutics, Inc.’s price target?

The average price target for Keros Therapeutics, Inc. is 22.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $13.00. The average price target represents 60.47% Increase from the current price of $13.71.

What do analysts say about Keros Therapeutics, Inc.?

Keros Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of KROS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Keros Therapeutics (KROS) Stock Forecast & Price Target

KROS Analyst Ratings

KROS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Keros Therapeutics

KROS Analyst Recommendation Trends

KROS Financial Forecast

KROS Earnings Forecast

KROS Sales Forecast

KROS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts